OSAKA, Japan & CAMBRIDGE, Mass., November 12, 2026--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States
Takeda Pharmaceutical is reiterated as a hold, with concerns about its ability to replace major drug revenues and current valuation. Read more on TAK stock here.
Stock price rises to highest level in more than 8 years on expectations
Japanese drugmaker launches Orzeyful, once thought impossible to develop
Find out why Takeda Orzeyful is on TIME's list of 2026's best inventions.
Takeda is rated a buy, reflecting recent drug approval, a robust future pipeline, global reach & an investment-grade rating. Click for more on TAK stock.
Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base. For investors watching Takeda stock today, the core issue is how that performance and pipeline story stack up against what the business is actually generating in revenue. Takeda shares are up 120.5% over 5 years, which raises the question of how much of that gain is supported by the company’s sales...
Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in adults with moderate-to-severe plaque psoriasis, with results presented at the 2026 European Academy of Dermatology & Venereology Congress. A particularly important finding is that zasocitinib delivered more than 2.5 times as many patients with complete...
Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that investigational pill zasocitinib outperformed deucravacitinib on skin clearance measures in adults with moderate to severe plaque psoriasis. Taken together with Takeda Pharmaceutical’s oncology pipeline updates and recent leadership change in Spain, the psoriasis data arrives during a period of strong market performance, with the share price up 17.6% year to date and a...
BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of
Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.
OSAKA, Japan & CAMBRIDGE, Mass., September 22, 2026--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (briga
Sept 18 () - Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India. (Reporting by Kashish Tandon in Bengaluru; Editing by Sonia Cheema).
Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase […]
MALMO, Sweden & WILMINGTON, Del., September 09, 2026--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15–16 in Boston.
This is the newest page. Registered accounts read further back.